Therapies in amyotrophic lateral sclerosis - Beyond riluzole

Current Opinion in Pharmacology

Volumn 2, Issue 3, 2002, Pages 302-309

  Morrison, Karen E ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; AMANTADINE; ANTIOXIDANT; ANTIVIRUS AGENT; BRANCHED CHAIN AMINO ACID; CREATINE; CYCLOSPORIN; DEXTROMETHORPHAN; GABAPENTIN; GANGLIOSIDE; GLUTAMIC ACID; GUANIDINE; IMMUNOGLOBULIN; LAMOTRIGINE; METHISOPRINOL; NEUROTROPIC AGENT; PENICILLAMINE; PHYSOSTIGMINE; PLECONARIL; RILUZOLE; SELEGILINE; TACRINE; THREONINE; TILORONE; TOPIRAMATE; UNINDEXED DRUG; VERAPAMIL; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN MITOCHONDRION; CELL CULTURE; CELL DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG TARGETING; HUMAN; HYPOXIA; IMMUNOMODULATION; MITOCHONDRIAL RESPIRATION; MOTONEURON; NERVE EXCITABILITY; NEUROFILAMENT; NEUROTROPISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SCREENING; STEM CELL TRANSPLANTATION;

EID: 0036605466     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00169-8     Document Type: Review

References (73)

1. A controlled trial of riluzole in amyotrophic lateral sclerosis. The ALS/riluzole study group
2. Riluzole for amyotrophic lateral sclerosis (ALS)/ motor neuron disease (MND)
3. Any placebo controlled trial of riluzole would surely be unethical now
4. Amyotrophic lateral sclerosis
5. A case of amyotrophic lateral sclerosis with a very slow progression over 44 years
6. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS
7. Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded
8. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
9. British motor neuron disease twin study
10. Mutation in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
11. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis
12. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2
13. Genetically engineered models relevant to neurodegenerative disorders: Their value for understanding disease mechanisms and designing/testing experimental therapeutics
14. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)
15. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: Associated mutations develop motor neuron disease
16. Apoptosis in amyotrophic lateral sclerosis: A review of the evidence
17. Novel drug development for amyotrophic lateral sclerosis
18. Antioxidant therapy in ALS
19. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis
20. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons
21. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis
22. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis
23. Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics
24. Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model
25. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice
26. Protection of cultured spinal motor neurons by estradiol
27. The copper chelator D-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis
28. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice
29. Prevention of mutant SOD1 motoneuron degeneration by copper chelators in vitro
30. Motoneuron cell death and neurotrophic factors: Basic models for development of new therapeutics strategies in ALS
31. Neurotrophic factors
32. Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo-controlled study
33. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis
34. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
35. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: A reappraisal using a new HPLC method with coulometric detection in a large cohort of patients
36. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis
37. Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis
38. Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls
39. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals
40. The pharmacology and mechanism of action of riluzole
41. Review of clinical trials
42. Mitochondrial involvement in amyotrophic lateral sclerosis
43. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients
44. Mitochondria in sporadic amyotrophic lateral sclerosis
45. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis
46. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations
47. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
48. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders
49. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: Preliminary results
50. Apoptosis in amyotrophic lateral sclerosis: A review of the evidence
51. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis
52. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model
53. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
54. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
55. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction
56. A randomized controlled trial of recombinant interferon beta-1a in ALS
57. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis
58. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis
59. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS
60. Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients
61. Treatment of ALS with pleconaril
62. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: Potential therapy of SMA
63. Genetic mapping of a mouse modifier gene that can prevent ALS onset
64. Stem cells step closer to the clinic: Paralysis partially reversed in rats with ALS-like disease
65. Stem cells - Hype and hope
66. Stem cells and neuropoiesis in the adult human brain
67. The potential for the use of mononuclear cells from human umbilical cord blood in the treatment of amyotrophic lateral sclerosis in SOD1 mice
68. hNT neurons delay onset of motor deficits in a model of amyotrophic lateral sclerosis
69. Nutritional assessment and survival in ALS patients
70. Bipap improves survival and rate of pulmonary function decline in patients with ALS
71. Imaging and neurochemical markers for diagnosis and disease progression in ALS
72. Serum and cerebrospinal fluid biochemical markers of ALS
73. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis